<DOC>
	<DOCNO>NCT01949792</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) rFVIIa ( activated coagulation factor VII ) follow one single injection 270 microg/kg compare three injection 90 microg/kg rFVIIa patient haemophilia .</brief_summary>
	<brief_title>A Trial Investigating Pharmacokinetics Pharmacodynamics rFVIIa Patients With Haemophilia A B With Without Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male patient confirm diagnosis severe congenital haemophilia A B ( high 1 % FVIII FIX ) without inhibitor coagulation factor VIII IX , base medical record Congenital acquire coagulation disorder congenital haemophilia A B Any clinical sign know history arterial thrombotic event previous deep vein thrombosis pulmonary embolism ( define available medical record ) Use anticoagulant ( e.g . unfractionated low molecular weight heparin , vitaminK antagonist , direct thrombin inhibitor factor Xa inhibitor ) Bleeding prophylactic treatment FVIII FIX immune tolerance induction ( ITI ) treatment trial period</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>